AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34690272 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 74
Study 32739355 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial breast irradiation
Number of subjects: 0
Study 32739355 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy
Number of subjects: 0
Study 35505251 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-epileptic drugs (AEDs)
Number of subjects: 9261
Study 35505251 — intervention group
Group type: EXPERIMENTAL
Intervention: HDACi anti-epileptic drugs (AEDs)
Number of subjects: 9261
Study 35505251 — intervention group
Group type: COMPARATOR
Intervention: Other anti-epileptic drugs (AEDs)
Number of subjects: 9261
Study 32139486 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 152
Study 32139486 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 152
Study 32139486 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Acupuncture and Placebo acupuncture)
Number of subjects: 152
Study 36153033 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening only
Number of subjects: 880
Study 36153033 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and provision of resource sheet(s)
Number of subjects: 880
Study 36153033 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and provision of resource sheet(s) plus social work assistance
Number of subjects: 880
Study 33008451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.8 μg/kg administered for 10 min before anesthesia)
Number of subjects: 94
Study 33008451 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (equal volume)
Number of subjects: 94
Study 33008451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 94
Study 36271441 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote consenting used by 30/37 sites for 54/156 recruits
Number of subjects: 156
Study 36271441 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote site initiation visits (SIVs) conducted remotely
Number of subjects: 156
Study 36271441 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote data monitoring used by 5 sites
Number of subjects: 156
Study 33720960 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen D (injection gentamicin once daily for 2 days plus oral amoxicillin twice daily for 7 days)
Number of subjects: 0
Study 33720960 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (injection gentamicin once daily plus oral amoxicillin twice daily, both for 7 days)
Number of subjects: 0
Study 33720960 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C (once daily injection gentamicin plus injection procaine penicillin for 2 days, thereafter oral amoxicillin twice daily for 5 days)
Number of subjects: 0
Study 33720960 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen E (oral amoxicillin twice daily for 7 days)
Number of subjects: 0
Study 33720960 — intervention group
Group type: COMPARATOR
Intervention: Reference regimen A (injection gentamicin plus injection procaine penicillin both once daily for 7 days)
Number of subjects: 0
Study 32171429 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET-based target group
Number of subjects: 205
Study 32171429 — intervention group
Group type: COMPARATOR
Intervention: Conventional target group
Number of subjects: 205
Study 32171429 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 205
Study 35179608 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 50
Study 35179608 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual trigger point pressure release
Number of subjects: 50
Study 35179608 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 50
Study 33846237 — intervention group
Group type: EXPERIMENTAL
Intervention: BPCA-sponsored studies
Number of subjects: 10918
Study 32725731 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine evaluation of gastric aspirates
Number of subjects: 0
Study 32725731 — intervention group
Group type: COMPARATOR
Intervention: Selective evaluation of gastric aspirates
Number of subjects: 0
Study 34676542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine 0.7 mg/kg/day
Number of subjects: 206
Study 34676542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine 0.2 mg/kg/day
Number of subjects: 206
Study 34676542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine 0.4 mg/kg/day
Number of subjects: 206
Study 34676542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 32859616 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric-restriction diet (goal: 10% weight-loss)
Number of subjects: 438
Study 32859616 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic-exercise (225 min/week moderate-to-vigorous activity)
Number of subjects: 438
Study 32859616 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diet+exercise
Number of subjects: 438
Study 32859616 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 438
Study 35725652 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCs transplantation
Number of subjects: 21
Study 35725652 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCs transplantation combined with exercise
Number of subjects: 21
Study 32278340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical debridement with hand and powered instruments and 980-nm diode laser application (test group, N=38)
Number of subjects: 73
Study 32278340 — intervention group
Group type: COMPARATOR
Intervention: Mechanical debridement alone (control group, N=35)
Number of subjects: 73
Study 32278340 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 73
Study 32502358 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 32
Study 32502358 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard medication only)
Number of subjects: 32
Study 33828845 — intervention group
Group type: EXPERIMENTAL
Intervention: EMBRACE intervention
Number of subjects: 1490
Study 34607469 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 500
Study 34607469 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome adjudication committee assessment
Number of subjects: 500
Study 34607469 — intervention group
Group type: COMPARATOR
Intervention: Misclassification by central assessor
Number of subjects: 500
Study 33849503 — intervention group
Group type: EXPERIMENTAL
Intervention: Music exposure at 70 dB SPL
Number of subjects: 87
Study 33849503 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study 33849503 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplug group
Number of subjects: 87
Study 35314481 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including phone surveys, center-specific audit/feedback, educational package, and academic detailing visit
Number of subjects: 5312
Study 35314481 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 5312
Study 33667699 — intervention group
Group type: EXPERIMENTAL
Intervention: active-tDCS (M1-S0, 2 mA, 20 min)
Number of subjects: 58
Study 33667699 — intervention group
Group type: COMPARATOR
Intervention: sham-tDCS
Number of subjects: 58
Study 32809893 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline legumain levels
Number of subjects: 4883
Study 32809893 — intervention group
Group type: EXPERIMENTAL
Intervention: Legumain levels at 1 month
Number of subjects: 4883
Study 34061572 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging behaviors of individuals with chronic aphasia over a 7-day period.
Number of subjects: 20
Study 34814693 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections at the time of surgery
Number of subjects: 100
Study 34814693 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injections)
Number of subjects: 100
Study 32470244 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia crowns
Number of subjects: 50
Study 32470244 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel crowns (SSCs)
Number of subjects: 50
Study 33706543 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Pilates
Number of subjects: 46
Study 33706543 — intervention group
Group type: COMPARATOR
Intervention: Home exercises
Number of subjects: 46
Study 33305552 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (4.8 g·day-1 for four weeks)
Number of subjects: 16
Study 33305552 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study 35104197 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomothetic clinical feedback
Number of subjects: 329
Study 35104197 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized clinical feedback
Number of subjects: 329
Study 35104197 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined clinical feedback
Number of subjects: 329
Study 35104197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral participants
Number of subjects: 329
Study 33819508 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 84
Study 33819508 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 84
Study 33819508 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous immunotherapy (SCIT) and Sublingual immunotherapy (SLIT)
Number of subjects: 84
Study 35562815 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR care pathway (assessment clinic at three months and up to six follow-up telephone calls over 12 months)
Number of subjects: 27
Study 35562815 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR care pathway
Number of subjects: 27
Study 35562815 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 27
Study 32268436 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset abiraterone acetate plus prednisone (AA+P) therapy
Number of subjects: 159
Study 32268436 — intervention group
Group type: COMPARATOR
Intervention: Late-onset abiraterone acetate plus prednisone (AA+P) therapy
Number of subjects: 159
Study 32268436 — intervention group
Group type: EXPERIMENTAL
Intervention: Missed early-onset therapy assignment (MEC)
Number of subjects: 159
Study 36498825 — intervention group
Group type: EXPERIMENTAL
Intervention: XP-Endo Shaper Sequence (XPS)
Number of subjects: 120
Study 36498825 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-sequence Self-Adjusting File (SAF)
Number of subjects: 120
Study 36498825 — intervention group
Group type: COMPARATOR
Intervention: Manual K-files (HKF)
Number of subjects: 120
Study 32321565 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of chemotherapy (CT)
Number of subjects: 200
Study 32321565 — intervention group
Group type: COMPARATOR
Intervention: Two cycles of chemotherapy followed by two cycles of durvalumab and subsequent maintenance treatment with durvalumab every 4 weeks
Number of subjects: 200
Study 32299371 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily weight monitoring
Number of subjects: 396
Study 34458922 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam therapy
Number of subjects: 236
Study 34458922 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal replacement therapy on the day of reoperation
Number of subjects: 236
Study 34458922 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 236
Study 34458922 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal replacement therapy on reoperation
Number of subjects: 236
Study 34458922 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 236
Study 34458922 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal cultures containing Klebsiella spp.
Number of subjects: 236
Study 34458922 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic source of infection
Number of subjects: 236
Study 34458922 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiological failure
Number of subjects: 236
Study 33547717 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance (measured by The Human Connection Scale, range: 16-64)
Number of subjects: 672
Study 33547717 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance
Number of subjects: 672
Study 33547717 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (measured by Functional Assessment of Cancer Therapy-Palliative Care, range: 0-184)
Number of subjects: 672
Study 32557921 — intervention group
Group type: EXPERIMENTAL
Intervention: MCA pulsatility index < 5th percentile
Number of subjects: 856
Study 32557921 — intervention group
Group type: EXPERIMENTAL
Intervention: UCR Z-score above gestational-age-specific thresholds (1.5 at 32-33 weeks and 1.0 at 34-36 weeks)
Number of subjects: 856
Study 32557921 — intervention group
Group type: COMPARATOR
Intervention: Normal outcome
Number of subjects: 856
Study 36348417 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular embolization of the middle meningeal artery (eMMA)
Number of subjects: 0
Study 36348417 — intervention group
Group type: COMPARATOR
Intervention: Conventional neurosurgical treatment (control)
Number of subjects: 0
Study 33496811 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate
Number of subjects: 14
Study 33496811 — intervention group
Group type: COMPARATOR
Intervention: Control (no inhaled fluticasone propionate)
Number of subjects: 14
Study 32660260 — intervention group
Group type: EXPERIMENTAL
Intervention: EP test-guided group (n=57) with adjunctive posterior wall isolation (PWI) performed in those with positive results (PWI subgroup; n=24)
Number of subjects: 111
Study 32660260 — intervention group
Group type: EXPERIMENTAL
Intervention: EP test-guided group (n=57)
Number of subjects: 111
Study 32660260 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=54)
Number of subjects: 111
Study 35303880 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986020 (LPA1 antagonist)
Number of subjects: 140
Study 35303880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 33125587 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Ambassador Program (TAP), an 8-session, peer-based, behavioral intervention
Number of subjects: 84
Study 33125587 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Ambassador Program (TAP)
Number of subjects: 84
Study 32950113 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour workshop on teamwork
Number of subjects: 70
Study 32950113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 35800232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cable-pin system
Number of subjects: 50
Study 34590586 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐learning group (n=12)
Number of subjects: 21
Study 34590586 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching methods group (n=9)
Number of subjects: 21
Study 33962365 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-FO (morning FO intake: DHA 1010 mg; EPA 240 mg; evening placebo: DHA 40 mg; EPA 15 mg)
Number of subjects: 20
Study 33962365 — intervention group
Group type: EXPERIMENTAL
Intervention: DN-FO (evening FO intake: DHA 1010 mg; EPA 240 mg; morning placebo: DHA 40 mg; EPA 15 mg)
Number of subjects: 20
Study 33962365 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-FO
Number of subjects: 20
Study 33962365 — intervention group
Group type: COMPARATOR
Intervention: BF-FO and DN-FO
Number of subjects: 20
Study 32289716 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rTMS protocol (conventional 10-Hz rTMS or intermittent theta burst stimulation)
Number of subjects: 189
Study 32289716 — intervention group
Group type: COMPARATOR
Intervention: Standard rTMS protocol
Number of subjects: 189
Study 36208057 — intervention group
Group type: EXPERIMENTAL
Intervention: MNZ + blue light
Number of subjects: 251
Study 36208057 — intervention group
Group type: COMPARATOR
Intervention: MNZ
Number of subjects: 251
Study 36208057 — intervention group
Group type: COMPARATOR
Intervention: blue light
Number of subjects: 251
Study 33674933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling at 18°C (Group 1)
Number of subjects: 156
Study 33674933 — intervention group
Group type: COMPARATOR
Intervention: Cooling at 22°C (Group 2)
Number of subjects: 156
Study 33674933 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 156
Study 32305223 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous CABG
Number of subjects: 2253
Study 32305223 — intervention group
Group type: COMPARATOR
Intervention: No previous CABG
Number of subjects: 2253
Study 36300550 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg tablet) from Glenmark
Number of subjects: 6
Study 36300550 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg tablet) from Citron
Number of subjects: 6
Study 36300550 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg tablet) from Harris
Number of subjects: 6
Study 36300550 — intervention group
Group type: COMPARATOR
Intervention: Fasted treatment
Number of subjects: 6
Study 36300550 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed treatment
Number of subjects: 6
Study 36300550 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 6
Study 35010402 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Resistance Intervention (SRI) program, home-based, consisting of 30 min of resistance exercise three times/week for 12 weeks, health education on sarcopenia.
Number of subjects: 80
Study 35010402 — intervention group
Group type: COMPARATOR
Intervention: Usual exercise (Control group).
Number of subjects: 80
Study 35302681 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab
Number of subjects: 838
Study 35302681 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab
Number of subjects: 838
Study 35302681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 838
Study 35302681 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing regimens of fremanezumab
Number of subjects: 838
Study 33003972 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 266
Study 33003972 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 266
Study 33214390 — intervention group
Group type: EXPERIMENTAL
Intervention: VIBEDE (novel iterative denoising and image enhancement technique)
Number of subjects: 50
Study 33214390 — intervention group
Group type: EXPERIMENTAL
Intervention: VIBEDE
Number of subjects: 50
Study 36115677 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted vasopressin injection (20 units mixed with 100 mL normal saline)
Number of subjects: 39
Study 36115677 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted vasopressin injection (20 units mixed with 200 mL normal saline)
Number of subjects: 39
Study 36115677 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted vasopressin injection (20 units mixed with 400 mL normal saline)
Number of subjects: 39
Study 33957292 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS combined with CT
Number of subjects: 67
Study 33957292 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS combined with CT
Number of subjects: 67
Study 33957292 — intervention group
Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 67
Study 32367124 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise 3 times per week for 3 months
Number of subjects: 100
Study 32367124 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 33595593 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4744
Study 33595593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study 32890862 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Sleep and Circadian Intervention (TranS‐C)
Number of subjects: 22
Study 33740346 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency percutaneous electrical nerve stimulation
Number of subjects: 40
Study 33740346 — intervention group
Group type: COMPARATOR
Intervention: Low frequency percutaneous electrical nerve stimulation
Number of subjects: 40
Study 616401456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous drip of 1200 mg of glutathione once a day for eight weeks
Number of subjects: 104
Study 616401456 — intervention group
Group type: COMPARATOR
Intervention: Intravenous drip of 0.4 g of inosine injection with 250 ml of 5% glucose once a day for eight weeks (Control)
Number of subjects: 104
Study 35651860 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiny Habits for Gratitude (n = 50)
Number of subjects: 154
Study 35651860 — intervention group
Group type: COMPARATOR
Intervention: Tiny Habits Control (n = 52)
Number of subjects: 154
Study 35651860 — intervention group
Group type: COMPARATOR
Intervention: Inactive Control (n = 52)
Number of subjects: 154
Study 35651860 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiny Habits for Gratitude (n = 50) at 1 month
Number of subjects: 154
Study 35651860 — intervention group
Group type: COMPARATOR
Intervention: Inactive Control (n = 52) at 1 month
Number of subjects: 154
Study 34633422 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-fat dairy
Number of subjects: 49
Study 34633422 — intervention group
Group type: COMPARATOR
Intervention: Reduced-fat dairy
Number of subjects: 49
Study 32222912 — intervention group
Group type: EXPERIMENTAL
Intervention: BC 007 (15 mg, 50 mg, 150 mg)
Number of subjects: 31
Study 32222912 — intervention group
Group type: EXPERIMENTAL
Intervention: BC 007 (150 mg)
Number of subjects: 31
Study 32222912 — intervention group
Group type: EXPERIMENTAL
Intervention: BC 007 (50 mg, 150 mg)
Number of subjects: 31
Study 32222912 — intervention group
Group type: EXPERIMENTAL
Intervention: BC 007 (300 mg, 450 mg, 750 mg, 1350 mg, 1900 mg)
Number of subjects: 31
Study 32222912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 35104787 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Mental Training (VRMT)
Number of subjects: 57
Study 35104787 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Mental Training (CMT)
Number of subjects: 57
Study 35104787 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57